Skip to main content
MDGL
NASDAQ Life Sciences

Madrigal Secures Three New Resmetirom Patents, Extending IP Protection to 2045

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$534.5
Mkt Cap
$12.374B
52W Low
$286.44
52W High
$615
52W Position info
87% above low
Off High info
13% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

MDGL sits 87% above its 52-week low of $286.44.

Summary

Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for resmetirom, the active ingredient in Rezdiffra, its approved MASH therapy. Two patents cover dosing refinements in F2/F3 patients—one for weight-based step-down with a moderate CYP2C8 inhibitor (protection to 2045) and another capping rosuvastatin at 20mg to reduce side effects (to 2042). A third patent covers a method of treating compensated cirrhosis (F4c), extending protection to 2042. This builds on the existing 2045 F2/F3 patent and strengthens the exclusivity runway for Rezdiffra, which generated $311M in Q1 2026 net sales. The expanded IP portfolio reduces near-term generic risk and supports the company's long-term commercial position in MASH. The F4c patent aligns with the ongoing Phase 3 outcomes trial, potentially broadening the label and market opportunity.

At the time of this announcement, MDGL was trading at $534.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $286.44 to $615.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

MDGL - Latest Insights

MDGL
Nov 06, 2026, 5:30 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $399.93
Real-time Price: $417.44 info
Change: +$17.50 (+4%) info
Market Cap: $9.701B info
MDGL
Nov 05, 2026, 10:35 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $408.99
Real-time Price: $417.44 info
Change: +$8.44 (+2%) info
Market Cap: $9.701B info
MDGL
Nov 03, 2026, 9:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $428.01
Real-time Price: $417.44 info
Change: -$10.57 (-2%) info
Market Cap: $9.701B info
MDGL
Nov 03, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $477.00
Real-time Price: $417.44 info
Change: -$59.57 (-12%) info
Market Cap: $9.701B info
MDGL
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $431.16
Real-time Price: $417.44 info
Change: -$13.72 (-3%) info
Market Cap: $9.701B info